Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia
September 2002
You'll see patients getting Aranesp (darbepoetin alfa), the new longer-acting erythropoietin analog for anemia.
Aranesp is approved for anemia associated with chronic renal failure...including patients on dialysis, and those not on dialysis.
It's also being studied for anemia due to cancer chemotherapy.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote